Kornimate/medical-research-clean huggingface dataset:
artificial intelligence supporting cancer patients across europe - the ascape project

Conditions: Breast Cancer; Prostate Cancer; Quality of Life; Survivorship; Toxicity

Summary: ascape (artificial intelligence supporting cancer patients across europe) is a collaborative research project involving 15 partners from 7 countries, including academic medical centers, smes (small and medium-sized enterprises), research centers and universities, aiming to leverage the recent advances in big data and ai (artificial intelligence) to support cancer patients' quality of life (qol) and health status. specifically, ascape aims to provide personalized- and ai-based predictions for qol issues in breast- and prostate cancer patients as well as suggest potential interventions to their physicians. this project has received funding from the european union's horizon 2020 research and innovation programme under grant agreement no 875351.


Eligibility criteria:
the patient selection process varies among the different study sites. three hospitals (sismanogleio general hospital athens (sgha), örebro university hospital (öuh), uppsala university hospital (uuh)) will include patients with newly diagnosed breast- (öuh, uuh) or prostate cancer (sgha, öuh) who are eligible for curative treatment with surgery (breast cancer in öuh and uuh; prostate cancer in nkua) or radiotherapy (prostate cancer; öuh). one hospital (barcelona) will include breast cancer survivors (at least 12 months after surgery or chemotherapy) with follow-up through the hospital. finally, careacross will include patients with breast- or prostate cancer through its online platform for patients seeking for the careacross services. inclusion criteria (breast cancer; orb and uppsala): * breast cancer diagnosis * no clinical evidence of metastatic disease * able for curative treatment with surgery with or without oncological treatment. inclusion criteria (breast cancer; barcelona) * prior early breast cancer who are at follow-up with at least 12 months after surgery or chemotherapy (whichever occurred last). inclusion criteria (breast cancer; careacross) * breast cancer diagnosis (as per self-reported) irrespective of stage and treatment. inclusion criteria (prostate cancer; sgha and orb) * proostate cancer diagnosis * no clinical evidence of metastatic disease * able for curative treatment with surgery with or without oncological treatment (sgha) or radiotherapy (with or without prior surgery) irrespectively the type of radiotherapy (external radiotherapy, brachytherapy, or combination). inclusion criteria (prostate cancer; careacross) * prostate cancer diagnosis (as per self-reported) irrespective of stage and treatment. exclusion criteria (common in all study sites): * inability to give informed consent * inability / no access to smartphones, applications or internet services * patients with known medical history of allergy to the wearable material.

Keywords: breast cancer prostate cancer quality of life survivorship artificial intelligence
brushite kidney stones: a registry and database of clinical and laboratory findings

Conditions: Nephrolithiasis

Summary: brushite kidney stones are a unique form of calcium phosphate stones that have a tendency to recur quickly if patients are not aggressively treated with stone prevention measures. little research has been undertaken to better understand the clinical history and potential urinary abnormalities that may predispose one to these troublesome kidney stones.

multiple treatment options are available for the treatment of kidney or ureteral calculi. treatment options include shock wave lithotripsy (swl; shock waves are transmitted through the body wall and focused onto the stone to break the stone into gravel), percutaneous nephrolithotomy (pnl; a small flank incision is made and a telescope inserted into the kidney to allow stone fragmentation and removal from the patient), and ureteroscopic lithotripsy (urs; a small telescope is inserted into the ureter or kidney and a laser is used to break up the stone into gravel). brushite is a unique form of calcium phosphate kidney stone that often has sub-optimal stone fragmentation with shock wave lithotripsy (heimbach et al, 1999). due to its swl resistance, brushite patients often undergo more invasive treatments such as urs or pnl to achieve a stone free status. brushite patients often have multiple stones and have a high likelihood of developing recurrences (new stone formation or regrowth of existing stone fragments), often within the first year after surgery. these patients may also have a history of anatomical abnormalities of the urinary tract or a history of prior renal or ureteral surgery (klee et al, 1991). a thorough review of the clinical, radiological and metabolic data of brushite patients has the potential to clarify a number of important points. many patients with brushite stones often have a history of non-brushite stones (e.g. calcium oxalate) predating the development of brushite stones and historical review is needed to define the factors contributing to this shift in stone composition. in addition, it has been shown that ct attenuation values can be used to predict stone composition (joseph et al, 2002). as a result, it is crucial to review the radiologic appearance of known brushite stones to identify specific radiographic characteristics and possibly allow a radiographic diagnosis of brushite to be established. finally, very little information has been reported on the urinary abnormalities in brushite patients. by carefully examining 24 hour urine data in a large population of brushite patients, information may be identified that can be used to provide improved management of specific abnormalities to prevent stone recurrences.

Eligibility criteria:
inclusion criteria: 1. male or female patients of methodist urology in indianapolis, in over the age of 18 with brushite stones. exclusion criteria: 1. patients unable to give informed consent

Keywords: brushite kidney stones nephrolithiasis
cerebral oximetry in cardiac surgery to reduce neurological impairment and hospital length-of-stay

Conditions: Cardiac Surgery; Neural Injury; Cerebral Ischemia

Summary: cerebral oximetry using near-infrared spectroscopy (nirs) has been shown to reduce the incidence of neurological dysfunction and hospital length-of-stay in adult cardiac surgery though not all studies agree. a previous audit using cerebral saturations at or above baseline showed improved neurological and length-of-stay outcomes.

this prospective, single centre, double-blinded controlled study randomized 182 consecutive patients, scheduled for cardiac surgical procedures using cardiopulmonary bypass. participants were randomized by concealed envelope prior to anaesthesia. nirs study group were managed perioperatively using our nirs protocol. the control group had standard management without nirs. primary outcomes were post-operative neurological impairment and hospital length-of-stay. secondary outcomes included ventilation times, intensive care unit length-of-stay, major organ dysfunction and mortality

Eligibility criteria:
inclusion criteria: patients undergoing elective cardiac surgery using cardiopulmonary bypass. patient over 18 years age. - exclusion criteria: emergency surgery. cardiac surgery without cardiopulmonary bypass. inability to perform test. persistent neurological conditions: recent stroke. dementia. alzheimer's disease parkinson's disease -
valproic acid, magnesium sulphate, rocuronium requirement, postoperative analgesia

Conditions: Cerebral Aneurysm

Summary: the investigators hypothesized that valproic acid will increase rocuronium requirement and mgso4 infusion would reduce requirement of muscle relaxant in craniotomy patients preloaded with sodium valproate.

magnesium sulfate (mgso4) is known to reduce requirement of muscle relaxant.

Eligibility criteria:
inclusion criteria: * 18- 65 years * american society of anesthesiology physical status 1,2 * scheduled for elective craniotomy for aneurysm clipping or for superficial temporal artery-middle cerebral artery anastomosis exclusion criteria: body mass index \ 24.9 kg m-2; neuromuscular, renal, cardiovascular or hepatic insufficiency; glasgow coma scale (gcs) \<15; allergy to the study drugs; medications influencing ndmrs; breast feeding; pregnancy; and preoperative epilepsy.

Keywords: craniotomy sodium valproate rocuronium
observational study of safety and efficacy of levemir® in type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: the study is conducted in asia. the aim of this observational study is to evaluate the weight change from baseline while using levemir® in subjects with type 2 diabetes mellitus under normal clinical practice conditions in india.


Eligibility criteria:
inclusion criteria: * any subject with type 2 diabetes exclusion criteria: * subjects with a hypersensitivity to insulin detemir or any of its excipient * children below 6 years * subjects who are pregnant, lactating or planning to become pregnant
efficacy, safety, and pharmacokinetics of rifaximin in subjects with severe hepatic impairment and hepatic encephalopathy

Conditions: Hepatic Encephalopathy

Summary: the purpose of the study is to evaluate the safety of rifaximin or placebo in subjects with severe hepatic impairment and hepatic encephalopathy.


Eligibility criteria:
inclusion criteria: * male or non-pregnant, non-breast feeding female ≥ 18 years old * in remission from demonstrated overt he * had ≥1 episode of overt he associated with liver disease within the last 6 months * meld score of ≥ 19 * has a close family member or other personal contact who is familiar with the subject's he, can provide continuing oversight to the subject and is willing to be available to the subject during the conduct of the trial exclusion criteria: * hiv * history of tuberculosis infection * chronic respiratory insufficiency * current infection and receiving antibiotics * renal insufficiency requiring dialysis * active spontaneous bacterial peritonitis infection * intestinal obstruction or has inflammatory bowel disease * active malignancy within the last 5 years * current gi bleeding or has had a gi hemorrhage within past 3 months * anemia

Keywords: hepatic encephalopathy liver failure hepatic insufficiency liver diseases brain diseases rifaximin cirrhosis
trental for the treatment of vertigo/dizziness/imbalance

Conditions: Dizziness; Vertigo

Summary: imbalance, dizziness and vertigo as a result of problems in the inner ear (vestibular dysfunction) are becoming increasingly more prevalent in americans 40 years of age and older. the symptoms have a severe impact on affected individuals with detrimental effects on work, travel, social and family life. these patients see doctors often with no relief in their symptoms. the most promising help for these patients is to use medication that will increase blood flow to the inner ear. pentoxifylline (trental) has been shown to increase microvascular blood flow.

one potential cause of vestibular dysfunction is a decrease in or insufficient blood flow to the inner ear. studies have shown that when the blood flow is decreased to the inner ear, patients will become dizzy and off balance. this study will use validated instruments to evaluate the effectiveness of trental in patients that present to our providers with vertigo, dizziness, or imbalance and meet inclusion criteria. they will be blinded and randomized to treatment or placebo, which they will take for \~12 weeks. patients will completed validated surveys 3 times (beginning, middle and end of study) as well as account for the number of times they have fallen and if they have missed any work due to their symptoms.

Eligibility criteria:
inclusion criteria: 1. adults 40 years and older 2. english as primary language 3. diagnosis of multisensory losses, presbystasis, bilateral vestibulopathy, central vascular insufficiency, small vessel circulatory disease, generalized imbalance, and idiopathic peripheral vertigo scoring at least 16 on the dizziness handicap inventory 4. willingness to complete surveys and take medication as prescribed exclusion criteria: 1. diagnosis of the following: benign paroxysmal positional vertigo, meniere's disease, vestibular migraine with headache, intracranial mass, perilymphatic fistula, or multiple sclerosis 2. history of cholesteatoma 3. prior ear surgery other than myringotomy and tube placement 4. prior radiation to head or neck 5. previous use of vestibulotoxic medications where the enrolling provider determines the drug exposure to be the cause of imbalance 6. use of blood thinning medications 7. intolerance/allergy to pentoxifylline or methylxanthines, as well as recent cerebral or retinal hemorrhage (past 3 months) 8. pregnant or lactating females.
the effect of a theory based educational intervention on medication adherence to and removes of related barriers in patients with bipolar disorder

Conditions: Patients With Bipolar Disorders

Summary: despite an increasing pharmacopoeia of effective medications for the treatment of bipolar disorder, patient outcomes continue to be impacted by treatment adherence. non-adherence to treatments is also a major obstacle in translating efficacy in research settings into effectiveness in clinical practice. non-adherence with bipolar disorder (bd) medication treatment dramatically worsens outcomes. reasons for non-adherence among individuals with bd are multi-dimensional, and it has been suggested that a multifaceted intervention will be more effective. the study is aimed to assess the effectiveness of a multifaceted intervention on enhancing medications adherence in patients with bipolar disorders.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years 2. meeting dsm-iv criteria for bipolar i or ii disorder 3. concurrently treated with a mood stabilizer 4. not currently in weekly or biweekly psychotherapy 5. persian speaking. exclusion criteria: * dsm-iv drug or alcohol misuse disorders (excluding nicotine), * pregnancy or planning pregnancy in the next year * requiring changing the drug or the dose of a mood stabilizer * evidence of severe dsm-iv borderline personality * unable or unwilling to give written informed consent. * an organic cerebral cause for bipolar disorder-for example, multiple sclerosis or stroke. * intellectual disability

Keywords: bipolar disorders medication adherence psychological intervention multifaceted intervention
target post-approval study

Conditions: Complex Regional Pain Syndrome (CRPS)

Summary: the purpose of this prospective, multicenter, single arm post-approval study is to demonstrate continued safety of the axium and proclaim neurostimulator system for dorsal root ganglion (drg) stimulation. the primary endpoint is the 12-month serious adverse event rate for permanent implants.

a maximum of 426 adult subjects with moderate to severe chronic, intractable, pain of the lower limbs due to crps types i and ii will undergo a trial of the axium or proclaim neurostimulator system across up to 45 study sites in the united states. only subjects who report a 50% or greater reduction in overall pain intensity through direct patient-reported percentage of pain relief will receive the permanent implant. subjects will then return to the office for follow-up at 1, 3, 6 and 12 months post-permanent implant.

Eligibility criteria:
inclusion criteria: * subject is male or female between ≥ 22 and ≤ 75 years of age. * subject has moderate to severe chronic intractable pain of the lower limbs resulting from complex regional pain syndrome (crps) types i or ii. * subject has a baseline visual analogue scale (vas) of ≥ 60 mm for overall pain at the time of the baseline assessment. * subject is willing and able to comply with the study requirements. * subject is able to provide written informed consent. exclusion criteria: * subject has an active implantable medical device including but not limited to cardiac pacemakers and cardiac defibrillators. * subject is currently involved in medically related litigation, including workers compensation. * subject has a life expectancy of less than one year. * subject is pregnant or of child bearing potential and not using adequate contraception as determined by the investigator. * subject has, or plans to have, a spinal cord stimulation system or infusion pump system implanted. * subject has, or plans to have, a peripheral nerve stimulation system (pns) or peripheral nerve field stimulation system (pnfs) implanted. * subject is considered to be a poor surgical or study candidate, which may include, but is not limited to the following: any medical, social, or psychological problem that could complicate the implant procedure and/or recovery from the implant procedure or could complicate the required procedures and evaluations of the study in the judgment of the investigator.

Keywords: complex regional pain syndrome (crps) chronic pain sjm-cip-10113
clinical audit on the managment in assiut university children hospital

Conditions: Rheumatic Fever

Summary: clinical audit on the managment of rheumatic fever in assiut university children hospital.

acute rheumatic fever,an auto immune response to group a streptococcus infection of the upper respiratory tract,may result in carditis.when the inflammation leads to permenant damage of the valves the individual has rheumatic heart disease. recurrences of rheumatic fever are likely in the absence of preventive measures and may cause further cardiac valve and muscle damage,leading to heart failure,stroke and premature death.bacterial endocarditis is also a complication.

Eligibility criteria:
inclusion criteria: * patients with confirmed diagnosis of rheumatic fever based on laboratory investigations. exclusion criteria: * no
anti-inflammatory effect of tocotrienol supplementation in subjects with moderately elevated inflammation

Conditions: Inflammation; Cardiovascular Risk Factor

Summary: the objective of this study is to address the anti-inflammatory effect of tocotrienol supplementation in subjects with moderately elevated inflammation. it is hypothesized that 6 months supplementation of tocotrienols will reduce inflammatory markers of subjects.

a double-blind, randomized, placebo-controlled, parallel study comparing the effect of tocotrienols vs. placebo will be conducted in subjects with moderately elevated inflammation. subjects will be supplemented with tocovid suprabio 200 mg twice daily or placebo for 6 months. fasting blood samples will be collected at baseline, 3 months, 6 months. a post-study fasting blood sample will be collected at 9 months.

Eligibility criteria:
inclusion criteria: * age 30-60 * elevated plasma hs-crp level of \> 1 mg/l \< 10 mg/l exclusion criteria: * subjects with very high ldl-cholesterol ≥ 4.9 mmol/l * subjects with very high hs-crp level ≥ 10 mg/l * pregnancy or lactation * current use of vitamin e or corticosteroids * significant hepatic and renal impairment * fever, cold or infection during bleeding day

Keywords: inflammation tocotrienols cardiovascular disease
transumbilical versus lateral transabdominal removal of benign adnexal masses via laparoscopy

Conditions: Postoperative Pain

Summary: in cases of benign adnexal mass laparoscopic surgery, women were randomized to two groups: transumbilical vs. transabdominal removal. need for pain medication, postoperative pain and patients´ satisfaction were assessed between the groups, as well as surgeons´ opinions and costs.

women assigned to laparoscopic surgery for removal of a benign adnexal mass were randomly divided into two groups as regards surgery: a transumbilical (tu) group (n=21) and a transabdominal (ta) group (n=21). general anesthesia and use of local anesthetics were standardized. visual analog scale (vas) scores for pain and side effects (nausea/vomiting) and the amount of postoperative analgesic used were recorded for 24 hours. investigators also investigated the expenses related to endobags and trocars. further, peri- and postoperative complications were recorded. investigators inquired about patient satisfaction as well as the surgeons' opinions of the alternative methods available.

Eligibility criteria:
inclusion criteria: * the criteria for inclusion were scheduled laparoscopy for oophorectomy, salpingo-oophorectomy or cyst enucleation. exclusion criteria: * the exclusion criteria were contraindications to any of the forms of medication used in the study (oxycodone, ketoprofen, paracetamol), * language difficulties (inability to understand and speak finnish or swedish) * and suspicion of malignancy.

Keywords: adnexal mass laparoscopy removal route postoperative pain
an fmri study on temporal discounting in bipolar disorder

Conditions: Bipolar Disorder; Suicidal Ideation; Depression

Summary: the investigators propose to explore the link between bipolar disorder, anxiety, and suicide by investigating intertemporal discounting in depressed, suicidal patients with bipolar i and ii disorder who have various levels of anxiety. the investigators will determine the effect of anxiety on their intertemporal discounting (small rewards now compared to larger rewards later) in a decision-making paradigm and investigate the associated functional neuroanatomy using functional magnetic resonance imaging (fmri).

among the various psychological properties of the decision making process is temporal discounting, which is a decrease in the subjective value of a good as a function of the amount of and delay to reward. the ability to decide between immediate versus future rewards depends on self-control and consideration of the future. we can reconceptualize suicide as intertemporal discounting with an interaction between cognition and mood. someone contemplating suicide weighs the time value of costs and benefits with shifting negative and positive valence systems. to the best of our knowledge, no one has assessed the interaction between mood symptoms, anxiety, and their impact on the temporal discounting paradigm in bipolar patients. if we better understood the difference between anxious, suicidal and non-anxious, suicidal bipolar patients, we could design more effective interventions to prevent this tragic outcome. we propose a novel paradigm to explore the link between bipolar disorder, anxiety, and suicide. if we conceptualize suicidal behavior and death by suicide as decisions, then it makes sense to examine key aspects of decision making in these patients. in particular, we can examine how mood, anxiety, and suicidal ideation and behaviors arise from patterns of decision making, along with neural correlates of decision-making, as assessed with fmri.

Eligibility criteria:
inclusion criteria: 1. meets dsm-iv criteria for bd i and ii current depressive episode 2. able to give written informed consent 3. age \> to 18 years and \< 65 years 4. currently suicidal as defined by a madrs suicide item score of \> 3 or previous history of serious suicidal ideation that required hospitalization. 5. all subjects need to have normal hearing and normal/corrected-to-normal vision. exclusion criteria: 1. medical illness or non-psychiatric medical treatment that would likely interfere with study participation 2. neurologic disorder, previous ect, or history of head trauma (i.e. known structural brain lesion potentially confounding mri results) 3. substance abuse within the past 3 months or current substance dependence (confirmed by mini) 4. left-handedness 5. contraindications to mri (metallic implants, claustrophobia, etc.) 6. subjects who need urgent psychiatric care requiring hospitalization (evaluated by clinicians).

Keywords: magnetic resonance imaging bipolar disorder suicidal ideation